ASSESSING THE ROLE OF PHOSPHORYLATED S6 RIBOSOMAL PROTEIN IN THE PATHOLOGICAL DIAGNOSIS OF PULMONARY ANTIBODY-MEDIATED REJECTION.

Date publication

octobre 2023

Journal

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CHENARD Marie-Pierre

Tous les auteurs :
Lunardi F, Vedovelli L, Pezzuto F, Le Pavec J, Dorfmuller P, Ivanovic M, Pena T, Wassilew K, Perch M, Hirschi S, Chenard MP, Sosa RA, Goddard M, Neil D, Montero-Fernandez A, Rice A, Cozzi E, Rea F, Levine DJ, Roux A, Fishbein GA, Calabrese F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37806601

Résumé

Pulmonary antibody-mediated rejection is still a challenging diagnosis as C4d has poor sensitivity. Previous studies have indicated that the phosphorylated S6 ribosomal protein, a component of the mammalian target of rapamycin (mTOR) pathway, is correlated with de novo donor-specific antibodies in lung transplantation. The objective of this study was to evaluate the phosphorylation of S6 ribosomal protein as a surrogate for AMR diagnosis in lung transplant patients.

Mots clés

AMR, antibody-mediated rejection, lung transplantation, mTOR pathway, p-S6RP

Référence

J Heart Lung Transplant. 2023 10 6;: